DV
Dividend Vision

APGE — Apogee Therapeutics, Inc.

Apogee Therapeutics, Inc. (APGE)

Total return is 691.5% over the past 3.1 years, 612.2 points ahead of SPY at 79.3%. Its deepest 1-year drawdown was 24.6%.

Apogee Therapeutics is a clinical-stage biotechnology company developing monoclonal antibodies and other biologics to treat inflammatory and immunology conditions including atopic dermatitis, asthma, eosinophilic esophagitis, and chronic obstructive pulmonary disease. The company's lead candidate, Zumilokibart, is in phase 2 trials for atopic dermatitis with earlier-stage programs in development across multiple indications. As a pre-revenue biotechnology company, it does not currently distribute dividends and appeals to investors with high risk tolerance seeking exposure to clinical-stage drug development.

APGE key facts

Asset type
Stock
Asset class
Equity
Inception date
07/13/2023
Distribution frequency
None
Last close
$134.55
Market cap
$10,183,785,472
Average volume
1479800.0
Beta
0.343
Payout ratio
0.0
Forward P/E
0.0
EPS
$-4.34